A warm welcome to the month 12 COLOSSUS annual plenary meeting was delivered by Coordinator Prof Annette Byrne (RCSI). An overview of the revised timelines, deliverables and impact as a result of GDPR was provided by Prof Annette Byrne and Dr Alice O’Farrell (RCSI). The COLOSSUS team reported on the progress made in 2018 and future plans. Read the rest of the story here.
Colorectal cancer is the third most common cancer in Europe. COLOSSUS aims to provide new and more effective ways to classify patients with a specific type of colorectal cancer (microsatellite stable RAS mutant metastatic colorectal cancer or MSS RAS mt mCRC) and to develop better treatments for them. Our ultimate goal is to deliver a personalised medicine approach for patients with MSS RAS mt mCRC that is currently not available.
Learn more about COLOSSUS here.
Grant agreement number 754923
EC contribution €5,996,359.50
Duration 60 months
Starting date 1 January 2018.